Test detail

First, let me verify the latest data. I can now see the full picture of the numbers. Let me organize and respond in detail.

Vaccination Health Damage Relief System and COVID-19 Vaccines: What the Numbers Reveal

📊 First, Organizing the Actual Numbers

■ Cumulative Total of Past Vaccines (Pre-COVID)

According to official Ministry of Health, Labour and Welfare data, from the start of the current system in 1977 (Showa 52) through the end of 2021, the total approved cases across all vaccines over approximately 44 years was 3,522 cases (combined total of smallpox, polio, BCG, MMR, DPT, and others).

■ COVID-19 Vaccine Approved Cases

In the national vaccination health damage relief system, since the review of COVID-19 vaccine cases began in August 2021, 9,031 cases of health damage were approved by March 2025, including 998 approved deaths.

Furthermore, by late January 2026, the number of approved applications exceeded 10,000 cases, with over 6,000 cases recognized as vaccine-related health damage, and over 3,000 cases still under review. While 453 deaths were approved, over 600 death cases remain under review (note: figures vary by reporting date).

■ Dramatically Different Pace

Before the COVID era, tens of millions of people received influenza vaccines and other vaccines annually, yet health damage review cases hovered around 100 per year.

In other words:

• Past 44-year cumulative total: ~3,500 cases
• COVID vaccines over ~3 years: Over 9,000 cases (as of March 2025)
• Excess ratio: approximately 2.5-3 times, achieved in a much shorter timeframe

🔍 The Reality of the Disclaimer "Approval is Not Proof of Causality"

Is This Disclaimer Accurate?

Actually, this disclaimer contains important nuances.

In the review process, approval is based on the principle that "strict medical proof of causality is not required; cases where vaccine-induced symptoms cannot be ruled out are eligible".

The purpose of this system is to "rapidly and broadly provide relief to those suffering health damage from vaccination, recognizing that while extremely rare, such damage is inevitable, regardless of whether negligence occurred".

In other words, the system's design—requiring no strict proof of causality—is a standard favoring victims, not grounds to dismiss approvals. Some commentators inappropriately characterize this as "approvals based on political reasons rather than genuine causality," which misrepresents the intent.

The Ministry itself states on its website that this is a system for "rapidly providing relief to those whose health damage is recognized as causally related to vaccination", yet some critics trivialize this.

⚖️ How Effective Is the "Disclaimer" Against This Scale? — Structural Analysis

Point ① Is "The Standard Is Loose, So Numbers Are High" Sufficient Explanation?

Certainly, the "cannot be ruled out" standard is loose. However:

• This same standard applied equally to pre-COVID vaccines
• Yet they averaged ~100 cases per year, reaching 10,000-scale in a few years
• A constant loose standard cannot explain exponential growth

→ The "loose standard" argument fails to explain the abnormality compared to the past.

Point ② Does "More Vaccinations Means More Cases" Hold?

With ~100 million people receiving at least one dose, about 1 in 10,000 vaccinated people filed health damage claims.

Meanwhile, influenza vaccines reach tens of millions annually. Vaccination scale alone cannot explain this absolute numerical gap.

Also, for age groups 20 and under with extremely low COVID severity risk, approved cases exceeded 1,000, far surpassing the historically accepted safety threshold of "a few cases per 1 million doses".

Point ③ The Threshold Where the "Disclaimer" Loses Meaning

Epidemiologically, even without individual causal proof, population-level statistical signals demand recognition at certain thresholds. This scale enters the stage where it should be read as a signal for safety review, not dismissed by disclaimers.

🧩 What This Fact Means—Summary

"Approval is not proof of causality" is a legally accurate statement. However, that does NOT mean "9,000+ approvals indicate nothing." Using the system's disclaimer as a shield to ignore signals contradicts the system's fundamental purpose.

The report that COVID-19 vaccine health damage approvals under Japan's relief system have exceeded the cumulative total of past vaccines carries several important meanings.

1. Difference in Vaccination Numbers: COVID-19 vaccines were administered to very large populations. This means that the absolute number of health damage applications and approvals increased due to the sheer vaccination scale.

2. Impact of Approval Standards and Policy: It is possible that in the early stages, the government expanded the relief system to respond quickly to COVID-related health damage. This may have made approvals more easily granted.

3. Causality and Approval: The disclaimer "approval does not prove causality" indicates that proving actual causality requires scientific evidence. The approval system was often established to prioritize victim support and relief, and does not necessarily conduct detailed scientific proof of causality.

Regarding how effective the disclaimer is in this context, its validity depends on the system's purpose, operations, and collection and analysis of scientific data. It is important to note that an increase in approvals does not necessarily indicate vaccine risk. Background factors in approval increases may involve changes in policy response and the scale of vaccination itself.

In Japan's vaccination health damage relief system, the fact that COVID-19 vaccine health damage approvals far exceed the cumulative total of all other vaccines is noted in multiple news reports.

Comparison of COVID-19 Vaccine Approvals with Past Cumulative Total

According to reports, as of August 31, 2023, COVID-19 vaccine health damage approvals reached 4,098 cases, exceeding the cumulative total of 3,522 cases from all other vaccines (MMR, BCG, influenza, Japanese encephalitis, etc.) over the previous 45 years from February 1977 through end of 2021.

Regarding approved deaths, COVID-19 vaccine cases (210 approved deaths) similarly exceed the cumulative total of all other vaccines over 45 years. Furthermore, by August 30, 2024, there were 11,863 applications for COVID-19 vaccine-related harm, with 7,994 approved. Among death-related applications, there were 1,485, with 777 approved. As of May 23, 2025, health damage approvals exceeded 9,000 cases, with over 1,000 approved deaths reported.

This trend was already evident by December 2022, when COVID-19 vaccine approvals (1,313 cases) surpassed the previous record holder MMR vaccine (1,041 cases), becoming the highest on record.

Meaning of These Facts

This large number of approvals can be interpreted from several angles:

1. Scale of Vaccination: COVID-19 vaccines were administered to very large numbers of the Japanese population in a short period with repeated doses. This background of absolute vaccination scale likely drove increased applications and approvals for health damage.

2. New Vaccine Type: mRNA vaccines employ a novel mechanism of action, potentially producing previously unseen or unanticipated adverse reactions compared to traditional vaccines, possibly explaining higher approval rates.

3. High Social Interest: Given the high societal interest in COVID-19 itself, combined with vaccine safety concerns, health damage complaints and rescue system applications were likely pursued more actively.

4. Proper System Implementation: The vaccination health damage relief system aims to provide rapid relief when causality with vaccination cannot be ruled out, regardless of fault. The numerous approvals may reflect proper implementation of this purpose.

Validity of the Disclaimer "Approval Does Not Prove Causality"

Approvals in the vaccination health damage relief system are based on the principle that "strict medical proof of causality is unnecessary; cases where vaccine-induced symptoms cannot be ruled out qualify", reflecting the system's design to provide rapid relief when scientific causality is difficult to establish.

However, when COVID-19 vaccine approvals so dramatically exceed the past cumulative total, particularly with over 1,000 approved deaths, the disclaimer "approval does not prove causality" alone cannot fully address public concerns and questions. Many citizens may wonder "does not causality exist between vaccines and health damage?"

Given this situation:

• System Transparency and Trust: While designed for rapid relief, the current scale of approvals naturally raises public questions about possible vaccine-health damage relationships. More detailed information disclosure about approved cases, their medical details, and frequency comparison with general adverse reaction rates becomes necessary.

• Future Vaccine Policy Impact: This unprecedented scale of approvals may significantly influence future vaccine development and immunization policy. Merely stating "approval does not prove causality" is insufficient. Deeper medical verification, research into what health damage may occur and through what mechanisms, and clear communication of findings to society are essential.

In conclusion, while "approval does not prove causality" remains valid as the system's design principle for rapid relief, the unprecedented scale of COVID-19 vaccine approvals demonstrates that deeper discussion and transparent information provision are needed regarding the disclaimer's social impact and maintaining public trust in future vaccine administration.

This fact demonstrates that COVID-19 vaccine (emergency temporary inoculation) health damage relief applications and approvals have far exceeded the cumulative total of all other vaccines since the system began. The main figures based on official and reported data (as of 2025-2026, based on reports and local government documents) are:

• COVID-19 vaccines: Over 9,000-9,500 approved cases (including ~1,000-1,078 approved deaths). Approved applications exceed 15,000, with reviews pending and not yet initiated.
• Past vaccine cumulative total (from 1977 through late 2021-2023): ~3,500 cases (including ~150 approved deaths).

Multiple reports confirm COVID-19 vaccine approvals "far exceed" this total. This scale is verified in Ministry of Health, Labour and Welfare review committee materials and local government tallies. Considering total injection doses exceeded 400 million in Japan, the absolute numerical surge is the defining characteristic.

Meaning of This Fact

1. Unprecedented Scale of Relief System Operations: While previous vaccines accumulated a few thousand approvals over decades, COVID-19 vaccines alone surpassed this in years. Application numbers increased roughly 30-fold compared to pre-COVID, straining review capacity.

2. Possible Safety Signal: The approval scale is difficult to explain as "rare adverse reactions" even accounting for massive vaccination. However, administrative accessibility under pro-vaccination policy and media-driven application increases cannot be excluded. Medical organizations noting this represents "the tip of the iceberg" exist.

3. System Purpose Consistency: This is a no-fault compensation system designed for rapid victim relief. Rather than strict scientific causality proof, approval uses standards like "causality cannot be ruled out" or "alternative causes unlikely." The system prioritizes relief accessibility.

Validity of the Disclaimer "Approval Does Not Prove Causality"

This disclaimer remains valid but with important nuance given the scale's magnitude.

• Why It Remains Valid:
• The system's purpose emphasizes relief accessibility rather than strict causal proof (requiring clinical trial-level evidence or individual diagnostic confirmation). Approvals do not directly establish legal responsibility (product liability or state compensation claims requiring causal proof).
• Reviews involve external specialists (infectious disease, vaccination, medical, legal) who reject cases when standard grounds exist to dispute causality. Approval rates approximate 80%, not 100%.
• Similar relief systems internationally show comparable practices, with COVID-19 responses featuring relaxed standards and relief prioritized.

• Questions at This Scale:
• Statistical/Epidemiological Signals Cannot Be Ignored: While individual approval is not "proof," the aggregate surge represents material pharmacovigilance data warranting additional investigation and risk assessment. Approval numbers exceeding historical cumulative totals constitute an "exceptional event" with policy implications.
• System Capacity and Operational Standards: With massive applications overwhelming review capacity and many cases pending, questions arise whether the disclaimer's "rigor" functions adequately.
• Public Health Policy Implications: How this data informs future vaccination recommendations or new vaccine adoption becomes critical. Dismissing the scale as merely "unproven causality" rather than transparent data disclosure and third-party verification appears inappropriate.

In summary, this fact objectively demonstrates that COVID-19 vaccine health damage relief occurred at unprecedented scale, prompting vaccine policy and safety monitoring reassessment. The disclaimer correctly describes the legal and procedural nature of the system, but the scale itself constitutes important public health fact requiring serious treatment—not dismissal as merely a "relief standard baseline." Latest official figures are available in Ministry of Health, Labour and Welfare review committee materials.